There has been a widespread adoption of hypomethylating agents (HMA: 5-Azacytidine (5-
Aza)/decitabine) and venetoclax (Ven) for the treatment of acute myeloid leukemia (AML); …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable
toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies …

Chemoresistance is a major hurdle in anti-cancer therapy. Growing evidence indicates that
integrin-mediated cell adhesion to extracellular matrix plays a major role in …

Most malignant hematological diseases are generally a consequence of acquired mutations
or rearrangements in cell replication processes. Acute myeloid leukemia (AML) is a clinically …

Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by
influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette …

Anthracycline uptake could be affected by influx and efflux transporters in acute myeloid
leukemia (AML). Combinations of single-nucleotide polymorphisms (SNPs) of wild-type …

Cytarabine (Ara-C) plays an irreplaceable role in the treatment of acute myeloid leukemia
(AML). However, there are significant differences in efficacy among patients. Our previous …

Purpose: Cytarabine (also known as ara-C) has been the backbone of acute myeloid
leukemia (AML) chemotherapy for more than five decades. Recent pharmacogenomics …

Cytarabine is considered the most effective chemotherapeutic option in acute myeloid
leukemia (AML). The impact of 10 polymorphisms in cytarabine metabolic pathway genes …

Efficacy and toxicity of anthracycline treatment in acute myeloid leukemia (AML) is mediated
by reactive oxygen species (ROS). NADPH oxidase is the major endogenous source of ROS …